Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply.

Gerrits, A J; Jakubowski, J A; Michelson, A D; Frelinger, A L

Gerrits, A J; Jakubowski, J A; Michelson, A D; Frelinger, A L.

Afiliação

Gerrits AJ; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jakubowski JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Michelson AD; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Frelinger AL; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

J Thromb Haemost ; 16(3): 607-608, 2018 03.

Article em En | MEDLINE | ID: mdl-29314666

Assuntos

Antagonistas do Receptor Purinérgico P2Y; Ticagrelor; Plaquetas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antagonistas do Receptor Purinérgico P2Y / Ticagrelor Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google